NICE recommends Keytruda (pembrolizumab) for second line treatment of NSCLC.- Merck Inc.
The National Institute for Health and Care Excellence (NICE) has published new draft guidelines endorsing the second line use of Keytruda (pembrolizumab) from Merck Inc., to treat locally advanced or metastatic PD L1-positive non-small-cell lung cancer (NSCLC) in adults who have had at least one chemotherapy (and targeted treatment if they have an epidermal growth factor receptor [EGFR]- or anaplastic lymphoma kinase [ALK] positive tumour). Therapy with Keytruda is to be stopped at two years of uninterrupted treatment. NICE has accepted a confidential price discount from Merck Inc.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.